Positions

Overview

  • Strategies for hematopoietic stem cell transplantation in chronic lymphoproliferative disorders. Toxicity of hematopoietic stem cell transplantation. Population outcomes of hematologic malignancies.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 LEAM versus CBV for conditioning in autologous hematopoietic stem cell transplantation for lymphomaBone Marrow Transplantation.  54:625-628. 2019
    2019 Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of originLeukemia & Lymphoma.  60:940-946. 2019
    2019 Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER studyLeukemia & Lymphoma.  60:894-903. 2019
    2019 Incidence and outcomes of rare paediatric non-hodgkin lymphomasBritish Journal of Haematology.  184:864-867. 2019
    2019 The Future of Chimeric Antigen Receptor T Cell Therapy for the Treatment of Multiple MyelomaBiology of Blood and Marrow Transplantation.  25:e73-e75. 2019
    2019 Mobilization of Hematopoietic Progenitor Cells for Autologous Transplantation Using Pegfilgrastim and Plerixafor: Efficacy and Cost ImplicationsBiology of Blood and Marrow Transplantation.  25:233-238. 2019
    2019 Comparative Analysis of Calcineurin Inhibitor–Based Methotrexate and Mycophenolate Mofetil–Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic TransplantationBiology of Blood and Marrow Transplantation.  25:73-85. 2019
    2019 Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapyLeukemia2019
    2018 Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrowLeukemia Research.  74:64-67. 2018
    2018 A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801Haematologica.  103:1915-1924. 2018
    2018 Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplantBone Marrow Transplantation.  53:1345-1348. 2018
    2018 Second primary malignancy after multiple myeloma-population trends and cause-specific mortalityBritish Journal of Haematology.  182:513-520. 2018
    2018 Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple MyelomaBiology of Blood and Marrow Transplantation.  24:1379-1385. 2018
    2018 Incidence and survival trends in mantle cell lymphomaBritish Journal of Haematology.  181:703-706. 2018
    2018 Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of 5 Tests and Treatments to Question in Blood and Marrow TransplantationBiology of Blood and Marrow Transplantation.  24:909-913. 2018
    2018 Infectious diarrhea in autologous stem cell transplantation: high prevalence of coccidia in a South American centerHematology, Transfusion and Cell Therapy.  40:132-135. 2018
    2018 Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: Final results from the PILLAR-2 randomized phase III trialAnnals of Oncology.  29:707-714. 2018
    2018 Incidence and outcomes of paediatric myelodysplastic syndrome in the United StatesBritish Journal of Haematology.  180:898-901. 2018
    2018 Excess mortality among 10-year survivors of classical Hodgkin lymphoma in adolescents and young adultsAmerican Journal of Hematology.  93:238-245. 2018
    2018 R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysisBritish Journal of Haematology.  180:534-544. 2018
    2018 Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myelomaJournal of Clinical Oncology.  36:859-866. 2018
    2017 Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: A center for international blood and marrow transplant research analysisBone Marrow Transplantation.  52:1616-1622. 2017
    2017 Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma—a “real world” studyHematological Oncology.  35:528-535. 2017
    2017 C-MYC–positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapyCancer.  123:4411-4418. 2017
    2017 Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR reportCancer.  123:3141-3149. 2017
    2017 Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapiesAmerican Journal of Hematology.  92:161-170. 2017
    2017 Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple MyelomaBiology of Blood and Marrow Transplantation.  23:269-277. 2017
    2016 Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validityLeukemia & Lymphoma.  57:2827-2832. 2016
    2016 Impact of marital status, insurance status, income, and race/ethnicity on the survival of younger patients diagnosed with multiple myeloma in the United StatesCancer.  122:3183-3190. 2016
    2016 Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decision-makingAmerican Journal of Hematology.  91:1044-1051. 2016
    2016 Mobilization of hematopoietic progenitor cells for autologous transportation: Consensus recommendationsRevista da Associação Médica Brasileira.  62:10-15. 2016
    2016 Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignanciesBritish Journal of Haematology.  175:55-65. 2016
    2016 Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older PatientsBiology of Blood and Marrow Transplantation.  22:1543-1551. 2016
    2016 Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recoveryJournal of Hematology & Oncology.  9. 2016
    2016 Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR OutcomesBiology of Blood and Marrow Transplantation.  22:1197-1205. 2016
    2016 Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndromeJournal of Clinical Oncology.  34:1864-1871. 2016
    2016 Reply to a note on the magnitude of hazard ratiosCancer.  122:1299-1300. 2016
    2016 Success of an International Learning Health Care System in Hematopoietic Cell Transplantation: The American Society of Blood and Marrow Transplantation Clinical Case ForumBiology of Blood and Marrow Transplantation.  22:564-570. 2016
    2016 Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical featuresCancer Causes and Control.  27:81-91. 2016
    2016 Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myelomaAmerican Journal of Hematology.  91:101-108. 2016
    2015 Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myelomaLeukemia & Lymphoma.  56:3320-3328. 2015
    2015 Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantationBone Marrow Transplantation.  50:1513-1518. 2015
    2015 Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: A center for international blood and marrow transplant research studyJournal of Clinical Oncology.  33:3741-3749. 2015
    2015 A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphomaBone Marrow Transplantation.  50:1416-1423. 2015
    2015 Nonbiological factors affecting survival in younger patients with acute myeloid leukemiaCancer.  121:3877-3884. 2015
    2015 The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning RegimenBiology of Blood and Marrow Transplantation.  21:1746-1753. 2015
    2015 Early mortality in multiple myelomaLeukemia.  29:1616-1618. 2015
    2015 Fewer scans, better careJournal of Clinical Oncology.  33:1624. 2015
    2015 Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donorBone Marrow Transplantation.  50:197-203. 2015
    2015 Changes in the use of radiation therapy for early classical Hodgkin lymphoma in adolescents and young adults: Implications for survival and second malignanciesLeukemia & Lymphoma.  56:2339-2343. 2015
    2015 Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body IrradiationBiology of Blood and Marrow Transplantation.  21:552-558. 2015
    2015 Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myelomaBiology of Blood and Marrow Transplantation.  21:701-706. 2015
    2015 Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow TransplantationBiology of Blood and Marrow Transplantation.  21:1155-1166. 2015
    2015 Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-hodgkin lymphomaCancer Control : Journal of the Moffitt Cancer Center.  22:87-94. 2015
    2015 Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myelomaBritish Journal of Haematology.  169:219-227. 2015
    2015 REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemiaBritish Journal of Haematology.  168:796-805. 2015
    2015 Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphomaLeukemia & Lymphoma.  56:645-649. 2015
    2014 Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myelomaBlood.  124:1915-1925. 2014
    2014 Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell TransplantationBiology of Blood and Marrow Transplantation2014
    2014 Lomustine use in combination with etoposide, cytarabine and melphalan in a brief conditioning regimen for auto-HSCT in patients with lymphoma: the optimal doseBone Marrow Transplantation.  49:1239-1240. 2014
    2014 Optimizing autologous stem cell mobilization strategies to improve patient outcomes: Consensus guidelines and recommendationsBiology of Blood and Marrow Transplantation.  20:295-308. 2014
    2014 Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: Analysis of transplantation timing and modalityJournal of Clinical Oncology.  32:273-281. 2014
    2014 Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: Implications for risk-stratificationBiology of Blood and Marrow Transplantation.  20:222-228. 2014
    2014 Features and outcomes of diffuse large B-cell lymphoma of the thyroid in a large contemporary cohortLeukemia & Lymphoma.  55:283-287. 2014
    2014 Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myelomaBiology of Blood and Marrow Transplantation.  20:402-408.e1. 2014
    2014 Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular LymphomaBiology of Blood and Marrow Transplantation.  20:951-959. 2014
    2014 Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: Guidelines from the american society for blood and marrow transplantationBiology of Blood and Marrow Transplantation.  20:1262-1273. 2014
    2014 Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant ResearchBiology of Blood and Marrow Transplantation.  20:89-97. 2014
    2014 Similar dynamics of intraapheresis autologous CD34+ recruitment and collection efficiency in patients undergoing mobilization with or without plerixaforTransfusion.  54:3131-3137. 2014
    2013 Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBIBlood.  122:3863-3870. 2013
    2013 Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myelomaBiology of Blood and Marrow Transplantation.  19:1615-1624. 2013
    2013 Risk and outcome of non-Hodgkin lymphoma among classical Hodgkin lymphoma survivorsCancer.  119:3385-3392. 2013
    2013 Hematopoietic cell transplantation for systemic mature T-cell non-hodgkin lymphomaJournal of Clinical Oncology.  31:3100-3109. 2013
    2013 Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: An analysis of 3691 casesBlood.  121:4861-4866. 2013
    2013 Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: Meta-analysis of trials with biological assignmentBone Marrow Transplantation.  48:562-567. 2013
    2013 Autologous and Allogeneic Transplantation for Burkitt Lymphoma Outcomes and Changes in Utilization: A Report from the Center for International Blood and Marrow Transplant ResearchBiology of Blood and Marrow Transplantation.  19:173-179. 2013
    2012 Association of age with fluorescence in situ hybridization abnormalities in multiple myeloma reveals higher rate of IGH translocations among older patientsLeukemia & Lymphoma.  53:2444-2448. 2012
    2012 Growth factor plus preemptive (just-in-time) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposureBone Marrow Transplantation.  47:1403-1408. 2012
    2012 Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchangeEuropean Journal of Haematology.  89:432-434. 2012
    2012 Pegfilgrastim-versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: Efficacy and cost analysisTransfusion.  52:2375-2381. 2012
    2011 Clonal diversity analysis using SNP microarray: A new prognostic tool for chronic lymphocytic leukemiaCancer Genetics.  204:654-665. 2011
    2011 Beyond CD34+ cell dose: Impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft functionTransfusion.  51:1995-2000. 2011
    2011 Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agentsAmerican Journal of Hematology.  86:699-701. 2011
    2011 Efficacy and Safety of Ciprofloxacin for Prophylaxis of Polyomavirus BK Virus-Associated Hemorrhagic Cystitis in Allogeneic Hematopoietic Stem Cell Transplantation RecipientsBiology of Blood and Marrow Transplantation.  17:1176-1181. 2011
    2011 Alternative donor transplantation after reduced intensity conditioning: Results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood graftsBlood.  118:282-288. 2011
    2011 Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilizationBone Marrow Transplantation.  46:523-528. 2011
    2011 Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilizationBone Marrow Transplantation.  46:64-69. 2011
    2010 Case report: Primary testicular lymphoma and AIDSAnnals of Clinical and Laboratory Science.  40:75-79. 2010
    2010 Testicular lymphomaSeminars in Oncology.  37:549-554. 2010
    2010 Overcoming HLA-DPB1 donor specific antibody-mediated haematopoietic graft failureBritish Journal of Haematology.  151:94-96. 2010
    2010 Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenibBritish Journal of Cancer.  103:796-801. 2010
    2010 Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitisAmerican Journal of Hematology.  85:627-629. 2010
    2010 Self-limited hemolysis due to anti-D passenger lymphocyte syndrome in allogeneic hematopoietic stem cell transplantationBone Marrow Transplantation.  45:772-773. 2010
    2009 Impact of allogeneic haematopoietic stem cell transplantation in the outcome of Ph+ acute lymphoblastic leukaemia treated with an imatinib-containing regimenBritish Journal of Haematology.  146:576-577. 2009
    2009 Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myelomaLeukemia & Lymphoma.  50:781-787. 2009
    2008 Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphomaBritish Journal of Haematology.  143:268-273. 2008
    2008 Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantationBritish Journal of Haematology.  142:404-412. 2008
    2008 Autologous HSC transplant in t-MDS/AML using cells harvested prior to the development of the secondary malignancyBone Marrow Transplantation.  42:497-498. 2008
    2008 Hodgkin lymphoma-related vanishing bile duct syndrome and idiopathic cholestasis: Statistical analysis of all published cases and literature reviewActa Oncologica.  47:962-970. 2008
    2008 Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantationBone Marrow Transplantation.  41:715-720. 2008
    2007 Renal cell carcinoma: New developments in molecular biology and potential for targeted therapiesOncologist.  12:1404-1415. 2007
    2007 Upstream Signaling Inhibition Enhances Rapamycin Effect on Growth of Kidney Cancer CellsUrology.  69:596-602. 2007
    2007 Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphomaCancer Treatment Reviews.  33:78-84. 2007
    2006 Woman with a papillary pulmonary lesion and a complex renal cystOncology.  20. 2006
    2005 Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinomaBritish Journal of Cancer.  92:2266-2277. 2005
    2005 Use of complementary and alternative medicine by Brazilian oncologistsEuropean Journal of Cancer Care.  14:143-148. 2005
    2005 Systemic chemotherapy induces microsatellite instability in the peripheral blood mononuclear cells of breast cancer patients.Breast Cancer Research.  7. 2005
    2004 Simultaneous occurrence of Hodgkin disease and tuberculosis: Report of three casesSouthern Medical Journal.  97:696-698. 2004
    2004 Commentary: The quality of randomised controlled trials may be better than assumedBMJ.  328:24-25. 2004
    2004 Evaluation of non-oncologist physician's knowledge and attitude towards cancer screening and preventive actionsRevista da Associação Médica Brasileira.  50:257-262. 2004
    2004 Negative results in cancer clinical trials - Equivalence or poor accrual?Controlled Clinical Trials.  25:525-533. 2004
    2003 White coat effect in breast cancer patients undergoing chemotherapyEuropean Journal of Cancer Care.  12:372-373. 2003
    1999 Pilot study of the combination of melphalan, carboplatin and etoposide as a conditioning regimen for relapsed lymphoma patientsActa Haematologica.  102:56-58. 1999
    1995 Main variations of the extrahepatic biliary system and their application to the so-called "split-liver" transplantation techniqueRevista do Hospital das Clínicas.  50:311-313. 1995

    Principal Investigator On

  • Private Grant  awarded by CELGENE CORPORATION 2019 - 2024
  • International Myeloma Foundation Study of the Outcomes of Myeloma Patients with t(11;14) Translocation  awarded by International Myeloma Foundation 2019 - 2024
  • Private Grant  awarded by AMGEN, INC. 2018 - 2023
  • Private Grant  awarded by GlaxoSmithKline 2018 - 2023
  • Private Grant  awarded by MUNDIPHARMA 2018 - 2023
  • Private Grant  awarded by JUNO THERAPEUTICS 2018 - 2023
  • Private Grant  awarded by CELGENE INTERNATIONAL II SÀRL 2018 - 2023
  • Private Grant  awarded by AMGEN, INC. 2018 - 2023
  • Private Grant  awarded by Janssen 2018 - 2023
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2017 - 2022
  • IUAB 1677: Optimizing Post-Allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma using Ibrutinib  awarded by VANDERBILT UNIVERSITY 2017 - 2022
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2017 - 2022
  • Private Grant  awarded by CELGENE CORPORATION 2017 - 2022
  • Private Grant  awarded by ABBVIE INC 2016 - 2021
  • Private Grant  awarded by KARYOPHARM THERAPEUTICS, INC. 2015 - 2020
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2020
  • Private Grant  awarded by ONYX PHARMACEUTICALS, INC. 2015 - 2020
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW 2018 - 2019
  • UAB 1324 -- A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) Versus HLA-Haploidentical Related Bone Marrow (Haplo-BM) for Patients with Hematologic Malignancies  awarded by National Marrow Donor Program 2016 - 2018
  • Private Grant  awarded by IMMUNOGEN, INC. 2017 - 2018
  • Investigator On

  • Private Grant  awarded by MIRAGEN THERAPEUTICS INC. 2019 - 2024
  • Private Grant  awarded by Genentech 2019 - 2024
  • Private Grant  awarded by RHIZEN PHARMACEUTICALS SA 2018 - 2023
  • Private Grant  awarded by RHIZEN PHARMACEUTICALS SA 2018 - 2023
  • Private Grant  awarded by Genentech 2018 - 2023
  • Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease, BMT CTN PROTOCOL #1507  awarded by National Marrow Donor Program 2017 - 2023
  • Private Grant  awarded by PHARMACYCLICS, INC. 2018 - 2023
  • A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML  awarded by National Marrow Donor Program 2017 - 2022
  • Private Grant  awarded by INCYTE CORPORATION 2017 - 2022
  • Private Grant  awarded by FATE THERAPEUTICS, INC. 2017 - 2021
  • Private Grant  awarded by EPIZYME - NEW 2016 - 2021
  • Private Grant  awarded by JUNO THERAPEUTICS 2016 - 2021
  • Private Grant  awarded by JUNO THERAPEUTICS 2016 - 2021
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2016 - 2021
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2021
  • Private Grant  awarded by MedImmune 2010 - 2020
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2015 - 2020
  • Molecular Characterization of Myeloma and Related Asymptomatic Precursor States  awarded by National Cancer Institute/NIH/DHHS 2014 - 2020
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2020
  • Southwest Oncology Group Purchase Service Agreement  awarded by Oregon Health & Science University 2015 - 2020
  • Private Grant  awarded by Genentech 2018 - 2020
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2015 - 2020
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2014 - 2019
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC 2017 - 2019
  • Private Grant  awarded by INCYTE CORPORATION 2018 - 2019
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2018 - 2019
  • BMT CTN 1302- Multicenter Phase II, Double Blinded, Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma  awarded by National Marrow Donor Program 2017 - 2019
  • Prospective Observation of Cardiac Safety with Proteasome Inhibition (PROTECT)  awarded by VANDERBILT UNIVERSITY 2017 - 2019
  • Private Grant  awarded by FATE THERAPEUTICS, INC. 2016 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2012 - 2018
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2013 - 2018
  • Private Grant  awarded by Genentech 2015 - 2018
  • Private Grant  awarded by Gilead Sciences 2013 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2012 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2017 - 2018
  • Private Grant  awarded by INCYTE CORPORATION 2013 - 2018
  • Private Grant  awarded by PHARMACYCLICS, INC. 2015 - 2018
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2014 - 2018
  • Private Grant  awarded by Genentech 2016 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2014 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2016 - 2017
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2012 - 2017
  • Private Grant  awarded by ARRAY BIOPHARMA 2015 - 2016
  • Private Grant  awarded by GlaxoSmithKline 2013 - 2016
  • Private Grant  awarded by MedImmune 2012 - 2016
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2011 - 2015
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2013 - 2014
  • Education And Training

  • Doctor of Philosophy in Cell / Cellular Biology and Anatomical Sciences, University of Sao Paulo 2007
  • Doctor of Medicine, University of Sao Paulo 1999
  • University of Sao Paulo, Internship 2000
  • Wayne State University Program, Residency 2008
  • University of Sao Paulo, Residency 2003
  • Mayo Clinic, Postdoctoral Fellowship 2007
  • University of Colorado Aurora, Postdoctoral Fellowship 2006
  • Full Name

  • Luciano Costa